199 related articles for article (PubMed ID: 35869805)
21. Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM; Claudiani S; O'Hare M; Szydlo R; Gerrard G; Foskett P; Foroni L; Milojkovic D; Apperley JF; Khorashad J
Br J Haematol; 2022 Apr; 197(1):52-62. PubMed ID: 34997766
[TBL] [Abstract][Full Text] [Related]
22. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
23.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
24. Response to Imatinib therapy is inferior for e13a2
Greenfield G; McMullan R; Robson N; McGimpsey J; Catherwood M; McMullin MF
BMC Hematol; 2019; 19():7. PubMed ID: 31073408
[TBL] [Abstract][Full Text] [Related]
25. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
[TBL] [Abstract][Full Text] [Related]
27. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
[TBL] [Abstract][Full Text] [Related]
28. Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene.
Dmytrenko IV; Fedorenko VG; Shlyakhtychenko TY; Sholoyko VV; Lyubarets TF; Malinkina TV; Dmytrenko OO; Balan VV; Kravchenko SM; Martina ZV; Tovstogan AO; Minchenko JM; Dyagil IS
Probl Radiac Med Radiobiol; 2015 Dec; 20():328-40. PubMed ID: 26695912
[TBL] [Abstract][Full Text] [Related]
29. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Marcé S; Xicoy B; García O; Cabezón M; Estrada N; Vélez P; Boqué C; Sagüés M; Angona A; Teruel-Montoya R; Ferrer-Marín F; Amat P; Hernández-Boluda JC; Ibarra MM; Anguita E; Cortés M; Fernández-Ruiz A; Fontanals S; Zamora L; On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300312
[TBL] [Abstract][Full Text] [Related]
30. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
31. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
Kim DD; Lee H; Kamel-Reid S; Lipton JH
Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
[TBL] [Abstract][Full Text] [Related]
33. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
34. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
Auewarakul CU; Huang S; Yimyam M; Boonmoh S
Acta Haematol; 2006; 116(2):114-9. PubMed ID: 16914906
[TBL] [Abstract][Full Text] [Related]
35. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
36. Distribution of
Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
[TBL] [Abstract][Full Text] [Related]
37. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
[TBL] [Abstract][Full Text] [Related]
38. The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
Ghalesardi OK; Khosravi A; Azizi E; Ahmadi SE; Hajifathali A; Bonakchi H; Shahidi M
Leuk Res; 2021 Feb; 101():106512. PubMed ID: 33524640
[TBL] [Abstract][Full Text] [Related]
39. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
